A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has alre ady cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing. ...read more read less